Domov › Kolorektalni rak › Colorado › Denver
Klinične študije za Kolorektalni rak v Denver, CO
23 študij za Kolorektalni rak išče udeležence na lokacijah v Denver in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.
Uradno besedilo študije (angleško)
Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →
The Vanguard Study: Testing a New Way to Screen for Cancer
Vključevanje udeležencevVabljeni zdravi prostovoljci
- Kaiser Permanente-Franklin, Denver
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Vključevanje udeležencevFaza 1/2
- Rocky Mountain Cancer Center, Denver
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Vključevanje udeležencevOpazovalna študijaVabljeni zdravi prostovoljci
- AdventHealth Porter, Denver
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Vključevanje udeležencevFaza 3
- Intermountain Health Cancer Center Saint Joseph, Denver
- Intermountain Health Saint Joseph Hospital - Research Office, Denver
- Intermountain Health Saint Joseph Hospital, Denver
- in še 3
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
Vključevanje udeležencevFaza 1/2
- Sarah Cannon Research Institute (SCRI), Denver
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
Vključevanje udeležencevFaza 3
- Rocky Mountain Cancer Centers, Denver
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Vključevanje udeležencevFaza 3
- Rocky Mountain Cancer Centers, Denver
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
Vključevanje udeležencevFaza 1/2
- SCRI at HCA Health One, Denver
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
Vključevanje udeležencevFaza 1
- SCRI Denver, Denver
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
Vključevanje udeležencevFaza 1
- Sarah Cannon Research Institute at HealthOne, Denver
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
Vključevanje udeležencevFaza 1
- Sarah Cannon Research Institute, Denver
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Vključevanje udeležencevFaza 1/2
- Rocky Mountain Cancer Center, Denver
- Sarah Cannon Research Institute at HealthONE, Denver
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Vključevanje udeležencevFaza 1
- Sarah Cannon Research Institue At Healthone, Denver
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
Vključevanje udeležencevFaza 3
- Rocky Mountain Cancer Centers, LLP, Denver
- Rocky Mountain Cancer Centers, LLP, Denver
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
Vključevanje udeležencevFaza 1
- Sarah Cannon Research Institute at HealthONE, Denver
CT-95 in Advanced Cancers Associated With Mesothelin Expression
Vključevanje udeležencevFaza 1
- Context Investigational Site, Denver
A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)
Vključevanje udeležencevFaza 2
- Rocky Mountain Cancer Center - Primary, Denver
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Vključevanje udeležencevFaza 1
- Sarah Cannon Research Institute at HealthONE, Denver
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
Vključevanje udeležencevFaza 1/2
- SCRI - Denver, Denver
Exogenous and Endogenous Risk Factors for Early-onset Colorectal Cancer
Vključevanje udeležencevOpazovalna študijaVabljeni zdravi prostovoljci
- Department of Medicine-Gastroenterology, Denver Veterans Affairs Medical Center, University of Colorado Hospital, Denver
A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
Vključevanje udeležencevFaza 1
- Sarah Cannon Cancer Institute at HealthONE, Denver
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Vključevanje udeležencevOpazovalna študija
- Kaiser Permanente-Franklin, Denver
- Colorado Blood Cancer Institute, Denver
- Rocky Mountain Cancer Centers-Midtown, Denver
- in še 1
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Vključevanje udeležencevFaza 1/2
- Sarah Cannon Research Institute at HealthONE, Denver
Študije za Kolorektalni rak v drugih mestih
- Houston, TX102 študij
- New York City, NY78 študij
- Nashville, TN69 študij
- Boston, MA63 študij
- Los Angeles, CA59 študij
- Arlington, VA52 študij
- St. Louis, MO50 študij
- San Antonio, TX46 študij
- Philadelphia, PA44 študij
- Grand Rapids, MI40 študij
- Baldwin Park, CA37 študij
- Chicago, IL34 študij
Druge študije v Denver
- Metastatski rak29 študij
- Rak dojke29 študij
- Nemalicelični pljučni rak27 študij
- Množni mielom27 študij
- Melanom19 študij
- Rak prostate19 študij
- Rak (vse vrste)18 študij
- Rak jajčnikov16 študij
- Rak pljuč16 študij
- Rak endometrija15 študij
- Non-Hodgkinov limfom14 študij
- Rak trebušne slinavke13 študij
Vir: ClinicalTrials.gov, podatki pridobljeni 6. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.